September 27, 2017 / 10:14 PM / 3 months ago

BRIEF-Canada's PMPRB hearing panel issues decision in Soliris case

Sept 27 (Reuters) -

* Canada’s Patented Medicine Prices Review Board hearing panel issues decision in Soliris case

* Canada’s PMPRB says panel found that the price of Soliris (Eculizumab) 10 mg/ml was and is excessive under sections 83 and 85 of the patent act

* Canada's PMPRB says panel ordered Alexion to lower price of soliris in canada as of sept 20 to no higher than lowest price in 7 comparator countries Source text - bit.ly/2fswmSk Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below